Your session is about to expire
← Back to Search
TAA-Specific CTL Therapy for Lymphoma (TACTAL Trial)
TACTAL Trial Summary
This trial is for patients who have a type of lymph gland disease called Hodgkin or non-Hodgkin lymphoma which has come back, or may come back, or has not gone away after treatment. This is a research study using special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.
TACTAL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTACTAL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TACTAL Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Hodgkin or non-Hodgkin lymphoma.I have been diagnosed with Hodgkin or non-Hodgkin lymphoma.I am currently taking corticosteroids.I am allergic to azacitidine or mannitol.I am currently taking corticosteroids.I am currently dealing with a severe infection.I am not pregnant or breastfeeding.I do not have an active HIV, hepatitis B, or hepatitis C infection.I have not had serious heart problems in the last 6 months.I have advanced liver cancer.I am not pregnant and will use two forms of birth control or have had surgery to prevent pregnancy.I am 18 or older with an active disease.I am 18 or older and have had a stem cell transplant from myself or an identical twin.I am 18 or older with active disease and eligible for azacytidine plus multiTAA-T cell treatment.I am under 18 and have an active disease.My oxygen level is above 95% without extra oxygen after having radiation therapy.I can do most activities but may need help.I haven't received any standard cancer treatments, including rituximab, for at least a week.My kidney function, measured by creatinine, is within the normal range for my age.
- Group 1: Antigen-Escalation Stage
- Group 2: Dose-Escalation Study Stage
- Group 3: azacytidine and multiTAA T cells Stage
- Group 4: Pediatric multiTAA T cells Stage
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any positions currently available for this trial?
"As of the last modification on April 4th 2022, this clinical trial is not actively seeking participants. According to records hosted by clinicialtrials.gov, there are 1957 other studies that remain open for recruitment at present."
Can you provide a synopsis of prior research involving Antigen-Escalation Stage?
"Presently, 174 Antigen-Escalation Stage trials are in progress. Of those trials, 32 are at the Phase 3 level. While primarily based out of Saint Louis Missouri, these studies have been implemented across 5671 sites worldwide."
What maladies can be addressed with the Antigen-Escalation Stage approach?
"Antigen-Escalation Stage is the most popular treatment for malignant neoplasms, with it also being beneficial to those suffering from 20-30% blasts, neutropenia and/or thrombocytopenia, as well as anemia."
What is the highest possible number of participants enrolled in this trial?
"Patient recruitment for this trial is currently inactive. It was initially posted on January 1st 2012 and last modified April 4th 2022. For those exploring alternate clinical trials, there are presently 1783 studies recruiting participants with hodgkin disease and 174 Antigen-Escalation Stage medical experiments searching for candidates."
What risks do patients undertaking Antigen-Escalation Stage face?
"Our experts at Power gave this Antigen-Escalation Stage a score of 1 since it is only in the first phase of trials - meaning there is restricted information on both its efficacy and safety."
Share this study with friends
Copy Link
Messenger